Tag
Parmax Pharma Limited
7 articles
A significant shift in control is underway at Parmax Pharma, as Dhiren C. Shah and Sunil C. Shah are set to acquire a majority stake through a share purchase agreement, preferential allotment, and a mandatory open offer. This acquisition, valued at approximately ₹10.04 crore, will trigger a change in promoters and result in the consortium potentially holding up to 57.06% of the company. However, the company's financial performance remains a concern, with a net loss of ₹4.16 crore for FY26 and a qualified auditor's report citing accounting non-compliances and unauthorized insurance claims, alongside contraventions of regulatory directives, highlighting potential risks for investors.
Parmax Pharma EGM Approves Capital Hike and Preferential Issue
Parmax Pharma shareholders approved four resolutions at the July 2, 2026 EGM, including an increase in authorized share capital.
Shareholders passed a special resolution to issue 31,37,586 equity shar
Parmax Pharma EGM Approves Capital Hike and Preferential Issues
Parmax Pharma shareholders approved four resolutions at an EGM held on July 2, 2026, including an increase in authorized share capital.
Shareholders passed a special resolution to issue 31,37,586 equi
Parmax Pharma EGM Approves Capital Hike, Preferential Issue
Parmax Pharma held an EGM on July 2, 2026, approving four key resolutions including an increase in authorized share capital.
Shareholders approved a preferential issue of 31,37,586 equity shares to no
Parmax Pharma PAC Acquires 2.76% Stake Off-Market
Abhay Chinubhai Shah (PAC 8) acquired 249,394 equity shares (2.76%) of Parmax Pharma on June 18, 2026 via off-market transaction.
The acquisition was made at ₹35.00 per share from three individual sel
Parmax Pharma PAC Acquires 53,520 Shares
Rupa Sunil Shah acquired 53,520 equity shares in Parmax Pharma via off-market transaction on June 16, 2026.
Total shareholding of acquirer and PACs increased to 7,68,320 shares, representing 20.54% of
Parmax Pharma Acquirers Seek Majority Control via SPA
Acquirers led by Dhiren C. Shah and Sunil C. Shah to acquire control of Parmax Pharma through share purchase agreement, preferential allotment, and open offer.
SPA executed at ₹35 per share for 43,210
Parmax Pharma FY26 Net Loss at ₹4.16 Crore
Board approved audited standalone FY26 results showing net loss of ₹4.16 crore and quarterly loss of ₹58.43 lakh.
Auditors issued qualified report highlighting unsanctioned ₹3.51 crore insurance claim